TNFSF10 and neoplasm: In particular, the IC50s of RGR-TRAIL for CRC cells, including COLO205, HCT116, LS174T, LIM1215, and HCT8, were 10–40 times lower than those of TRAIL for these cells (Figure 2(E, F)), indicating that fusion to the tumor-homing RGR peptide enhanced the cytotoxicity of TRAIL in CRC cells by improving its cell binding.